Clostridioides difficile Infection

Organism/Concept

C. difficile (ex-Clostridium difficile). Anaerobic, spore-forming, Gram+. NOT novel organism introduction — NORMAL FLORA DISRUPTION clearing way for overgrowth. Classic example of “normal flora turns harmful when disrupted” (see Normal Flora topic).

Pathogenesis

Precipitant (majority): BROAD-SPECTRUM ANTIBIOTIC exposure → disrupts competing microbiota → C. difficile proliferates + produces toxin. High-risk antibiotics: clindamycin, fluoroquinolones, broad-spectrum cephalosporins (broadest anaerobic flora suppression).

2 exotoxins: Toxin A (enterotoxin) + Toxin B (cytotoxin) — glucosylate/inactivate Rho GTPases → cytoskeleton disruption → cell death → inflammation → PSEUDOMEMBRANES (yellow-white fibrin/inflammatory/debris plaques) = pseudomembranous colitis.

Epidemic strain NAP1/BI/027: + binary toxin, ↑toxin A/B production → more severe/harder-to-treat disease.

Risk factors: advanced age, hospitalization (SPORES persist on surfaces, RESIST many disinfectants — hypochlorite needed, not alcohol, see Disinfection topic), PPI use, IBD.

Clinical Manifestations

Range: mild self-limited watery diarrhea → severe life-threatening colitis. Features: profuse watery diarrhea (±mucus, rarely bloody), cramping, fever, LEUKOCYTOSIS (can be striking — high WBC + new hospitalized-patient diarrhea = clue to test). Severe: fulminant colitis, TOXIC MEGACOLON, perforation — surgical emergencies. RECURRENT CDI: relapse after apparent successful Rx, meaningful minority — resistant spores persist through antibiotic course + already-disrupted microbiota remains vulnerable.

Laboratory Diagnosis

Built around TOXIN/TOXIN GENE detection, NOT simple culture (organism can colonize asymptomatically, non-toxigenic/suppressed) — testing based on presence alone overdiagnoses.

NAAT/PCR (toxin genes): highly sensitive, WIDELY USED. CAVEAT: detects GENETIC CAPACITY, not necessarily active production → risk of overdiagnosing colonization without compatible clinical picture.

EIA (toxin A/B protein): detects ACTUAL toxin, MORE SPECIFIC for active disease, LESS sensitive than NAAT.

GDH antigen: highly sensitive SCREEN (any strain, toxigenic or not), NOT specific for toxin production. Used as STEP 1 in TWO-STEP ALGORITHM (GDH screen → toxin EIA/NAAT confirmation on positives).

Test ONLY unformed/liquid stool with clinically significant diarrhea — testing formed stool/known colonization = misleading, discouraged.

Treatment

1st-line SHIFTED — metronidazole now INFERIOR, no longer preferred. Oral VANCOMYCIN or FIDAXOMICIN = preferred (local gut-lumen action, minimal systemic absorption). Fidaxomicin: costlier but LOWER recurrence rate (narrower spectrum, less additional flora disruption). Metronidazole: reserved for mild disease if preferred agents unavailable, or fulminant disease adjunct.

FMT (Fecal Microbiota Transplantation): effective, WELL-ESTABLISHED for RECURRENT CDI specifically. Directly restores disrupted microbiota (antibiotics treat active infection but don’t restore ecosystem preventing next relapse).

DISCONTINUE precipitating antibiotic where feasible = essential adjunct.

Prevention

Antimicrobial stewardship (single most effective population measure). Contact precautions + SOAP AND WATER hand hygiene (NOT alcohol handrub) for symptomatic patients — alcohol doesn’t kill spores, mechanical washing removes them. SPECIFIC EXCEPTION to usual alcohol-handrub preference (Standard Precautions topic). Hypochlorite-based room disinfection.

The Organism and Why This Infection Is Different

Clostridioides difficile (formerly Clostridium difficile) is an anaerobic, spore-forming, Gram-positive bacillus, and its central pathogenic story is genuinely different from almost every other infection in this section: it is not really a story of a novel organism being introduced, but of normal gut flora disruption clearing the way for an organism already present (or newly acquired) to overgrow unopposed — the same “normal flora turns harmful once disrupted” logic covered under Normal Microbial Flora, and, in fact, the single most classic clinical example of that principle in practice.

Pathogenesis

The essential precipitating event, in the overwhelming majority of cases, is broad-spectrum antibiotic exposure — antibiotics disrupt the colonic microbiota’s normal competitive suppression of C. difficile, allowing it (whether newly acquired from spores in the healthcare environment, or present at low, previously suppressed levels in the patient’s own gut) to proliferate to high numbers and produce toxin. Almost any antibiotic class can precipitate CDI, but clindamycin, fluoroquinolones, and broad-spectrum cephalosporins carry disproportionately high risk, reflecting how broadly and completely they suppress the competing anaerobic flora that would otherwise hold C. difficile in check.

Disease is driven by two large, related exotoxins: toxin A (an enterotoxin) and toxin B (a cytotoxin), both of which glucosylate and inactivate Rho-family GTPases in host colonic epithelial cells, disrupting the cytoskeleton, causing cell death, and driving the intense colonic inflammation that produces the disease’s characteristic pseudomembranes — raised, yellow-white plaques of fibrin, inflammatory cells, and cellular debris visible on colonoscopy, which give pseudomembranous colitis its name. Some strains (notably the epidemic NAP1/BI/027 ribotype) produce a third factor, binary toxin, and carry mutations increasing toxin A/B production, contributing to the more severe, harder-to-treat disease this particular strain is known for causing.

Risk factors beyond antibiotic exposure: advanced age, hospitalization/healthcare exposure (spores persist for long periods on surfaces and resist many standard disinfectants, as covered under Disinfection and Disinfectants — this is exactly why hypochlorite specifically, rather than routine alcohol-based products, is needed for effective environmental decontamination in a CDI outbreak setting, since alcohol does not reliably kill spores), proton pump inhibitor use, and underlying inflammatory bowel disease.

Clinical Manifestations

Presentation ranges from mild, self-limited watery diarrhoea to severe, life-threatening colitis. Characteristic features when present include profuse watery diarrhoea (occasionally with mucus, rarely grossly bloody), abdominal cramping, fever, and leukocytosis (which can be striking — a very high white cell count in a hospitalized patient with new diarrhoea is a genuine clinical clue prompting CDI testing). Severe disease can progress to fulminant colitis, toxic megacolon, and bowel perforation — genuine surgical emergencies. Recurrent CDI (a relapse after apparently successful initial treatment, occurring in a meaningful minority of patients) is a real, distinctive clinical problem specific to this infection, reflecting both the persistence of resistant spores in the gut through the initial antibiotic course and the fact that the gut microbiota, having already been disrupted once, often remains vulnerable to a repeat episode.

Laboratory Diagnosis

Testing is deliberately built around detecting toxin or toxin genes, not simply culturing the organism, since C. difficile can be present in the gut as an asymptomatic, non-toxin-producing or toxin-suppressed colonizer — testing (and treating) based on organism presence alone would substantially overdiagnose and overtreat, so diagnosis in a patient with compatible diarrhoeal symptoms rests on:

Nucleic acid amplification test (NAAT/PCR) for toxin genes — highly sensitive, now widely used, but with a real caveat: it detects the genetic capacity to produce toxin, not necessarily active toxin production at the time of testing, so a positive NAAT in a patient without a clinically compatible picture risks over-diagnosing simple colonization as true infection.
Enzyme immunoassay (EIA) for toxin A/B — detects actual toxin protein directly, more specific for genuinely active disease, but less sensitive than NAAT.
Glutamate dehydrogenase (GDH) antigen test — a highly sensitive screen for the organism’s presence (any strain, toxigenic or not) but not specific for toxin production, so it is typically used as a rapid initial screen in a two-step algorithm (GDH screen, followed by toxin EIA or NAAT confirmation on GDH-positive specimens) rather than as a standalone diagnostic test.

Testing should only be performed on unformed/liquid stool from a patient with clinically significant diarrhoea — testing formed stool, or testing simply because a patient is known to be colonized, produces misleading results and is explicitly discouraged.

Treatment

First-line therapy has shifted meaningfully in recent years, and the change reflects growing recognition that metronidazole, once standard, is genuinely inferior for this specific infection: oral vancomycin or fidaxomicin are now preferred first-line agents (both act locally within the gut lumen with minimal systemic absorption, which is exactly the property wanted for a purely intraluminal colonic infection); fidaxomicin, though costlier, is associated with a genuinely lower recurrence rate than vancomycin, reflecting its narrower spectrum and correspondingly less additional disruption to the remaining gut flora. Metronidazole is now reserved for milder disease where the preferred agents aren’t available, or as an adjunct in fulminant disease. Faecal microbiota transplantation (FMT) — transferring stool from a healthy donor to restore a disrupted microbiota — has become a genuinely effective, now well-established treatment specifically for recurrent CDI, directly addressing the underlying disrupted-flora vulnerability that antibiotics alone cannot fix, since antibiotics treat the active infection but do nothing to restore the competitive microbial ecosystem that would prevent the next relapse. Discontinuing the precipitating antibiotic wherever clinically feasible is an essential adjunct to any of the above.

Prevention

Antimicrobial stewardship (minimizing unnecessary broad-spectrum antibiotic use, the single most effective population-level preventive measure), contact precautions and hand hygiene with soap and water rather than alcohol-based handrub for actively symptomatic patients (since alcohol does not reliably kill C. difficile spores, while mechanical washing physically removes them — a genuine, specific exception to the usual preference for alcohol-based hand hygiene covered under Standard Precautions), and hypochlorite-based environmental disinfection of rooms housing CDI patients.